Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Elevance Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit has been filed against Elevance Health, Inc. for allegedly making false or misleading statements regarding the Medicaid redetermination process and its impact on the company's financial guidance [4]. - Investors who purchased Elevance common stock between April 18, 2024, and October 16, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][4]. - The deadline to move the Court to serve as lead plaintiff is July 11, 2025, and a lead plaintiff acts on behalf of other class members in directing the litigation [2]. Group 2: Allegations Against Elevance Health - The lawsuit claims that Elevance Health misrepresented its monitoring of cost trends associated with the Medicaid redetermination process, leading investors to believe that premium rates were sufficient to address the risk profiles of Medicaid patients [4]. - It is alleged that the company failed to disclose that the acuity and utilization of its Medicaid members were rising significantly, as healthier members were being removed from Medicaid programs [4]. - The misrepresentation of financial guidance and rate negotiations with states is said to have caused investor damages when the true situation was revealed [4]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's handling of Medicaid eligibility redeterminations and its financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may request to be appointed to lead the case by July 11, 2025 [2]. Group 2: Company Operations and Allegations - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits, which were paused during COVID but resumed in 2023 [3]. - The company claimed to be monitoring cost trends related to the Medicaid redetermination process and believed its negotiated rates were adequate for the risk profiles of Medicaid patients [4]. - Contrary to these claims, the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 3: Stock Performance and Financial Impact - Following Elevance's announcement on July 17, 2024, regarding increased Medicaid utilization, the stock price fell by $32.21, or nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, or nearly 11%, from $496.96 to $444.35 per share [7].

SAN FRANCISCO, July 03, 2025 (GLOBE NEWSWIRE) -- On July 2, 2025, investors in Centene Corp. (NYSE: CNC) saw the price of their shares of this normally low-volatility stock crash 40%, after the company withdrew its guidance, blaming preliminary discussions and data generated by an independent actuary, Wakely. The unusual circumstances and severe investor reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether Centene may have violated the securities laws. ...

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial guidance and cost trends related to Medicaid redetermination processes during the specified Class Period [1][4][5]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, Indiana, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Lawsuit Details - The lawsuit claims that Elevance misled investors by stating they were effectively monitoring cost trends and that premium rates negotiated with states were sufficient to cover rising Medicaid expenses [4]. - It is alleged that the company did not adequately reflect the impact of Medicaid redeterminations, which resulted in a higher utilization of Medicaid members who remained eligible, as those removed were generally healthier [5]. Investor Information - Investors who purchased Elevance securities during the Class Period have until July 11, 2025, to seek appointment as lead plaintiff representatives [2].

CHONGQING, CHINA - MAY 04: In this photo illustration, the logo of Oscar Health, Inc. is displayed ... More on a smartphone screen, with the company's branding visible in the background, on May 04, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)Getty Images On July 2nd, the health insurance sector underwent a notable decline following Centene (NYSE:CNC)'s retraction of its financial outlook, citing rising costs. Refer to – Centene: Is The Recent Decline In CNC Stock Justified? This ...

UnitedHealth Group (NYSE: UNH ) is currently one of the most difficult stocks to price and, consequently, to assign a specific rating. It is a time when a solid company with a business model that was previously known for its resilience is facingEquity Research Analyst with a broad career in the financial market, covered both Brazilian and global stocks. As a value investor, my analysis is primarily fundamental, focusing on identifying undervalued stocks with growth potential. Feel free to reach out for coll ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Elevance Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Elevance Health, Inc. stock purchase is from April 18, 2024, to October 16, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must file a motion with the Court by July 11, 2025, to represent other class members in the litigation [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked in the top for securities class action settlements and has recovered hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Elevance Health made false or misleading statements regarding the Medicaid redetermination process and its impact on financial guidance [4]. - It is claimed that the acuity and utilization of Medicaid members increased significantly, contrary to the company's assurances to investors [4]. - The misrepresentation of the situation led to investor damages when the true details became public [4].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may request to be appointed to lead the case by July 11, 2025 [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused the review of Medicaid eligibility during COVID, which resumed in 2023, leading to increased acuity and utilization among Elevance's Medicaid members [3][5]. Group 3: Financial Impact and Stock Performance - Elevance had previously stated it was monitoring cost trends related to Medicaid redetermination, but the actual increase in acuity and utilization was not reflected in its financial guidance for 2024 [4][5]. - Following announcements of increased utilization and missed earnings expectations, Elevance's stock price declined significantly: a drop of $32.21 per share (nearly 6%) on July 17, 2024, and a further decline of $52.61 per share (nearly 11%) on October 17, 2024 [6][7].

CANADA - 2025/04/06: In this photo illustration, the Centene Corporation logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesCentene Corporation (NYSE:CNC) experienced a challenging Tuesday evening, witnessing a 25% drop in shares during after-hours trading on July 1st. The significant decline in the healthcare giant's stock wasn’t merely another example of market fluctuations; it was di ...

Shares of Centene (NYSE: CNC) have tumbled more than 20% after the healthcare giant stunned investors by withdrawing its full-year financial guidance. The move echoed a similar shock from UnitedHealth Group (NYSE: UNH) in May, deepening concerns about rising costs and mounting pressure across the health insurance sector. In pre-market trading on Tuesday, Centene stock dropped as much as 26% to $41.57. This followed a previous close of $56.65, where CNC shares had gained 4.3% in the prior session. CNC one-da ...